Dihydropyridine Calcium Channel Blockers Amplify Gabapentin-Associated Dementia Risk: A Cohort Study

James W. Green, MS[1]; Luciana Mascarenhas Fonseca, PhD[2]; Michal Schnaider Beeri, PhD[2]; Sharon Sanz Simon, PhD[2,3]; James Scott Parrott, PhD[1]; Branimir Ljubic, MD, PhD[4]; Michael Schulewski[4]; Barbara Tafuto, PhD[1]; Suril Gohel, PhD[1]

1. Department of Health Informatics, Rutgers School of Health Professions, Newark, NJ
2. Herbert and Jacqueline Krieger Klein Alzheimer's Research Center, Brain Health Institute, Rutgers University, New Brunswick, NJ
3. Department of Psychiatry, Rutgers New Jersey Medical School, Newark, NJ
4. Office of Advanced Research Computing, Rutgers University, Piscataway, NJ

Corresponding Author: James W. Green, MS, Department of Health Informatics, Rutgers School of Health Professions, 65 Bergen Street, Newark, NJ 07107 (jg1984@shp.rutgers.edu)

Word Count: ~2,950 (main text) | Tables: 3 | Figures: 2 | References: 58 | Supplement: eTables 1–5, eFigure 1

Running Title: Gabapentin-CCB Co-use and Dementia Risk

Key Points

Question Does calcium channel blocker co-medication modify gabapentin-associated dementia risk?

Findings In this cohort study of 33,791 adults with hypertension, gabapentin users taking dihydropyridine calcium channel blockers had significantly higher dementia risk (HR, 2.22) than those without calcium channel blockers (HR, 1.15; interaction P = .004). The interaction was driven by dihydropyridine CCBs (HR, 3.20); non-DHP CCB users had insufficient events for reliable estimation. Among CCB users, the signal was concentrated in Alzheimer disease (G30: HR, 4.53) and unspecified dementia (F03: HR, 2.29), with a null finding for vascular dementia (F01: HR, 0.81). The interaction was independently replicated in the NIH All of Us Research Program.

Meaning Dihydropyridine calcium channel blocker co-medication was associated with amplified gabapentin-associated dementia risk, consistent with synergistic disruption of neuronal calcium signaling through complementary blockade of presynaptic $\alpha_2\delta$ channels and postsynaptic L-type calcium channels.

Abstract

Importance Gabapentin prescriptions reach 15.5 million Americans annually, and recent studies suggest gabapentin may increase dementia risk. Both gabapentin and calcium channel blockers (CCBs) affect neuronal calcium signaling, but whether CCB co-medication modifies gabapentin's dementia risk is unknown.

Objective To determine whether baseline CCB exposure modifies the association between gabapentin use and incident dementia, and whether this interaction shows CCB subtype specificity consistent with neuronal mechanism.

Design, Setting, and Participants Active comparator new-user cohort study using the Rutgers Clinical Research Data Warehouse (2018–2024), a multi-facility electronic health record system encompassing 405 clinical sites in northern New Jersey. Participants were adults aged 40 years or older with hypertension who initiated gabapentin or pregabalin. Data were analyzed from January through December 2025.

Exposures Gabapentin vs pregabalin initiation (active comparator), stratified by baseline dihydropyridine (DHP) or non-DHP CCB exposure.

Main Outcomes and Measures Incident dementia (ICD-10 codes). Inverse probability of treatment weighted (IPTW) Cox proportional hazards models estimated hazard ratios with multiplicative interaction terms. Validation included CCB subtype specificity, time-varying CCB analysis, falsification outcomes, lag analyses, and independent replication in the NIH All of Us Research Program.

Results Among 33,791 patients (mean [SD] age, 69.9 [11.5] years; 57.1% female; 47.6% White, 19.0% Black, 26.3% Other race; 502 dementia events; median follow-up, 1.22 years),

gabapentin was associated with approximately doubled dementia risk among CCB users (HR, 2.22; 95% CI, 1.42–3.47) compared with non-CCB users (HR, 1.15; 95% CI, 0.99–1.33; interaction P = .004). The interaction was driven by DHP CCBs (HR, 3.20; 95% CI, 1.81–5.67); verapamil users had insufficient events for reliable estimation (n = 348). Time-varying analysis confirmed the finding (HR, 1.52; 95% CI, 1.23–1.89; P = .0003). Among CCB users, the signal was strongest for Alzheimer disease (G30: HR, 4.53; 95% CI, 1.58–13.01) and unspecified dementia (F03: HR, 2.29; 95% CI, 1.27–4.14), but null for vascular dementia (F01: HR, 0.81), consistent with a neuronal rather than vascular mechanism. Independent replication in the NIH All of Us Research Program (N = 51,820) confirmed the CCB interaction using a time-varying design (HR, 2.74; 95% CI, 2.43–3.09). Four of 7 falsification outcomes were null.

Introduction

Gabapentin has become one of the most widely prescribed medications in the United States, with prescriptions increasing from 24 million in 2010 to nearly 59 million in 2024, reaching 15.5 million patients annually, with the highest prescribing rates among adults aged 65 and older.[1,2] Originally approved for epilepsy and postherpetic neuralgia, its use has expanded to include diabetic neuropathy, fibromyalgia, and various off-label indications.[3,4]

Recent studies have reported associations between gabapentin use and increased dementia risk. Patients with chronic low back pain receiving 6 or more gabapentin prescriptions had 29% higher dementia risk (RR, 1.29; 95% CI, 1.05–1.57).[5] Gabapentin-has been shown to be associated with cognitive and behavioral changes in older adults with existing cognitive impairment.[6] However, these and other studies compared gabapentinoid users to nonusers, a design that is vulnerable to confounding by indication.[7] Additionally, despite the high polypharmacy in older adults, these studies did not examine whether concomitant medications modify the association of gabapentin with dementia risk.

Calcium channel blockers represent a biologically plausible effect modifier. Gabapentin binds the $\alpha_2\delta$ subunit of voltage-gated calcium channels, reducing presynaptic calcium influx.[8–11] CCBs block L-type calcium channels critical for hippocampal long-term potentiation.[16,17–20] Importantly, CCB subtypes differ in their neuronal effects: dihydropyridine (DHP) CCBs penetrate the central nervous system and block neuronal L-type channels,[16,21–23] whereas verapamil shows cardiac selectivity with less CNS penetration.[16,21] The DREAM consortium found DHP CCBs associated with higher dementia risk compared with hydrochlorothiazide,[14] and verapamil has been identified as a potential neuroprotective agent in drug repurposing

studies.[15] This differential pattern provides a mechanistic hypothesis: if the interaction of gabapentin with CCB reflects neuronal L-type channel blockade, it should be present with DHPs but absent with verapamil.

Adults with chronic pain conditions requiring gabapentin have high rates of comorbid hypertension (pooled OR, 1.66; 95% CI, 1.28–2.15),[24] making gabapentin-CCB co-prescription common. We hypothesized that gabapentin and DHP CCBs interact to produce elevated dementia risk beyond what would be expected from either drug alone, and that this interaction would be absent with verapamil. Using an active comparator new-user design[26−29] with pregabalin as comparator, we sought to identify and validate a novel drug-drug interaction.

Methods

Study Design and Data Source

We conducted an active comparator new-user cohort study[26−29] using the Rutgers Clinical Research Data Warehouse (CRDW), integrating EHR data from the Rutgers health system (2018–2024). The CRDW encompasses 405 clinical facilities across the Robert Wood Johnson Health System in northern New Jersey, containing approximately 4 million patient records. This study used completely de-identified data and was determined to be Non-Human Subject Research by the Rutgers University Institutional Review Board (Non-Human Research Self-Certification; PI: Branimir Ljubic; Project: Hypertension — Data Analytics and Computer Science Modeling; certified August 15, 2024). Informed consent was not required. We followed STROBE guidelines for reporting.[58]

Study Population

Adults aged 40 years or older with diagnosed hypertension (ICD-10 I10–I16) who initiated gabapentin or pregabalin were eligible. The index date was the first gabapentinoid prescription. We required a 180-day baseline period with at least one healthcare encounter. Patients with any dementia diagnosis within 30 days of the index date were excluded to ensure incident outcomes. This washout period mitigates but does not eliminate reverse causality; prodromal cognitive symptoms may increase gabapentin prescribing independent of comorbidity, though the 30-day window and active comparator design substantially reduce this concern.

Exposures

The primary exposure was gabapentin versus pregabalin initiation. Pregabalin shares gabapentin's mechanism of action ($\alpha_2\delta$ subunit binding), therapeutic indications, and prescriber population, minimizing confounding by indication.[12,13,26] Baseline CCB exposure was defined as any CCB prescription in the 180-day pre-index period, further classified as DHP (amlodipine, nifedipine) or non-DHP (verapamil, diltiazem).

Outcomes

The primary outcome was incident dementia, defined as any ICD-10 dementia diagnosis code.[42–45] Secondary outcomes included dementia subtypes: F03 (unspecified dementia), G30 (Alzheimer disease), and F01 (vascular dementia). Sensitivity analyses used a strict phenotype requiring 2 or more dementia codes on separate dates.

Covariates

Baseline covariates included demographics (age, sex [as recorded in the EHR], race), comorbidities (diabetes, cardiovascular disease, stroke, chronic kidney disease, depression, anxiety, insomnia, obesity, cancer, chronic pain, neuropathy, epilepsy), healthcare utilization

(encounters, emergency visits, hospitalizations), and concomitant medications (antihypertensives, statins, opioids, benzodiazepines, SSRIs, SNRIs, proton pump inhibitors).

Statistical Analysis

Propensity scores for gabapentin initiation were estimated using logistic regression including all baseline covariates. IPTW targeting the average treatment effect in the treated (ATT) were calculated as stabilized weights truncated at the 1st and 99th percentile.[30–34] Covariate balance was assessed using standardized mean differences (SMD), with SMD less than 0.10 indicating adequate balance. Cox proportional hazards models with robust standard errors[59] estimated hazard ratios with multiplicative interaction terms for CCB exposure status.

Validation Framework

To distinguish true pharmacodynamic interaction from confounding or bias, we implemented comprehensive validation: time-varying CCB analysis (person-time split at CCB initiation among gabapentin users without baseline CCB); pre-index symptom balance (6 symptom families assessed in the 180-day pre-index period); lag analyses (3-month and 6-month exclusion periods); falsification outcomes (7 negative control conditions); non-$\alpha_2\delta$ anticonvulsant comparison (lamotrigine, levetiracetam, topiramate); duloxetine comparator analysis; comorbidity stratification (CKD, stroke, diabetes); intrasample replication (bootstrap, leave-one-site-out, split-half); and independent external replication in the NIH All of Us Research Program. Additional validation analyses (ARB overlap investigation, cancer and neuropathy balance, and pre-index symptom balance) are detailed in the Supplement (eTables 1–5, eFigure 1).

Results

Study Population

The final cohort included 33,791 patients: 28,058 gabapentin initiators (83.0%) and 5,733 pregabalin initiators (17.0%) (Figure 1). Mean age was 69.9 years (SD, 11.5), 57.1% were female, and the population was ethnoracially diverse (47.6% White, 19.0% Black, 26.3% Other race, 4.0% Asian). Baseline CCB exposure was present in 6,146 patients (18.2%), predominantly DHP CCBs (84.6% of CCB users). After IPTW, 40 of 42 covariates achieved adequate balance (SMD < 0.10); opioid and SNRI use remained imbalanced, likely reflecting pregabalin channeling for neuropathic pain (Table 1).

Table 1. Baseline Characteristics of Gabapentin and Pregabalin Initiators Before and After IPTW

Characteristic	**Gabapentin (n = 28,058)**	**Pregabalin (n = 5,733)**	**Unadjusted SMD**	**IPTW-Adjusted SMD**
Demographics				
Age, mean (SD), y	70.0 (11.6)	69.6 (11.2)	0.040	0.000
Female sex, %	56.9	58.1	0.023	0.004
White race, %	47.1	50.4	0.067	0.075
Black race, %	19.6	17.4	0.056	0.065
Asian race, %	4.0	3.4	0.031	0.028
Other race, %	29.6	28.9	0.017	0.019
Comorbidities, %				
Diabetes mellitus	23.9	24.8	0.021	0.000
Heart failure	7.1	5.4	0.071	0.021
Stroke history	2.9	1.6	0.084	0.045

Characteristic	Gabapentin (n = 28,058)	Pregabalin (n = 5,733)	Unadjusted SMD	IPTW-Adjusted SMD
Chronic kidney disease	9.1	7.6	0.054	0.010
Depression	5.7	6.3	0.025	0.001
Anxiety	7.5	8.6	0.040	0.003
Obesity	9.8	11.3	0.051	0.000
Cancer	12.0	11.0	0.034	0.002
Chronic pain	15.2	19.8	0.123	0.006
Neuropathy	3.4	4.1	0.036	0.003
Epilepsy	0.8	0.6	0.014	0.006
Concomitant Medications, %				
CCB (any)	18.5	16.6	0.051	0.019
Dihydropyridine CCB	15.7	14.1	0.045	0.017
Non-DHP CCB	3.4	2.7	0.043	0.028
SNRI	2.4	3.7	0.080	0.067

Abbreviations: CCB, calcium channel blocker; IPTW, inverse probability of treatment weighting; SMD, standardized mean difference. SMD < 0.10 indicates adequate balance. All 27 covariates with available data achieved SMD < 0.10 after IPTW adjustment. Chronic pain had the largest unadjusted SMD (0.123); IPTW reduced this to 0.006.

Primary Results

We identified an interaction whereby CCB co-medication was associated with substantially amplified gabapentin-associated dementia risk (Table 2, Figure 2). Among patients with baseline

CCB exposure, gabapentin (vs pregabalin) was associated with HR = 2.22 (95% CI, 1.42–3.47; P = .0005). Among patients without CCB exposure, HR = 1.15 (95% CI, 0.99–1.33; P = .072). The multiplicative interaction was significant (P = .004; E-value, 3.86).

Table 2. Drug-Drug Interaction Results and CCB Subtype Specificity

Group	**N**	**Events**	**HR (95% CI)**	**P Value**
Panel A. Primary Results: Drug-Drug Interaction by CCB Exposure Status				
CCB users	6,146	67	2.22 (1.42–3.47)	.0005
Non-CCB users	27,645	435	1.15 (0.99–1.33)	.072
Multiplicative interaction	—	—	—	.004
E-value for interaction	—	—	3.86	—
Panel B. CCB Subtype Specificity: Mechanistic Validation				
CCB Subtype	**N**	**Events**	**HR (95% CI)**	**Interpretation**
Any DHP CCB	5,198	52	3.20 (1.81–5.67)	Signal: CNS-penetrant
Amlodipine	4,862	49	2.98 (1.67–5.32)	Strongest DHP signal
Nifedipine	423	3	—	Sparse; not estimable
Verapamil	348	2	—	Sparse; not estimable
Diltiazem	774	13	—	Sparse; not estimable

Group	N	Events	HR (95% CI)	P Value
Non-DHP pool (diltiazem + verapamil)	~1,122	~18	1.97 (0.78–5.02)	Non-significant; P = .15

Abbreviations: CCB, calcium channel blocker; CI, confidence interval; DHP, dihydropyridine; HR, hazard ratio. All estimable models IPTW-weighted with robust standard errors. Panel A interaction P = .004; E-value = 3.86. Panel B non-DHP pool added as supplemental row; event-count limitation noted.

Sequence-Dependence

Among 1,527 chronic gabapentin users who initiated a new antihypertensive, DHP-CCB initiators (n = 381) showed no elevated dementia risk compared with ACE inhibitor initiators (n = 139). This asymmetry — gabapentin initiation in CCB users increases risk, but CCB initiation in chronic gabapentin users does not — is consistent with homeostatic neuronal adaptation and is examined in detail in a separate analysis with larger sample sizes.

Discussion

This study identifies a novel drug-drug interaction: DHP CCB co-medication substantially amplifies gabapentin-associated dementia risk. To our knowledge, this is the first demonstration that concomitant medications modify gabapentin's cognitive risk profile.

The DHP-specific signal (HR, 3.20) supports a neuronal-based mechanism. This pattern is unlikely to be explained by confounding, which would affect all CCB subtypes similarly, and instead reflects differential CNS penetration: DHP CCBs block neuronal L-type calcium channels critical for hippocampal long-term potentiation,[17–20] whereas verapamil shows cardiac

selectivity.[16,21] Independent evidence supports this differential: the DREAM consortium found DHP CCBs associated with higher dementia risk,[14] while verapamil has been identified as a potential neuroprotective agent.[15] Gabapentin and DHP CCBs may create synergistic disruption through complementary blockade at presynaptic ($\alpha_2\delta$) and postsynaptic (L-type) calcium channel sites, impairing calcium-dependent plasticity beyond what either drug produces alone.

The concentration of signal in F03 unspecified dementia and G30 Alzheimer disease among CCB users, with a null finding for F01 vascular dementia (HR = 0.81), provides additional support to mechanistic specificity.[46–48] If the interaction were driven by cerebrovascular effects, one would expect vascular dementia to be most affected, not least. The selective involvement of neurodegenerative subtypes is consistent with disruption of neuronal calcium signaling as the operative mechanism; future studies incorporating biomarkers of calcium dysregulation and longitudinal cognitive assessment are needed to investigate underlying mechanistic pathways. Preliminary pharmacogenomic analyses in All of Us whole-genome sequencing data suggest the interaction operates independently of APOE genotype and calcium channel gene variation, with full results reported separately. Drug-induced cognitive impairment accounts for 2.7% to 10% of dementia presentations and represents the most common cause of reversible cognitive impairment.[46] The short latency (240 days) and F03 involvement are consistent with this entity, which typically manifests as global cognitive decline affecting attention and processing speed rather than the domain-specific episodic memory impairment characteristic of Alzheimer disease. This has therapeutic implications: unlike neurodegeneration, drug-induced cognitive impairment may be reversible with medication adjustment.

The overall gabapentin effect among CCB nonusers (HR, 1.15) is consistent with prior findings (RR, 1.29),[5] suggesting the active comparator design replicates the known association while

identifying CCB exposure as a novel effect modifier. The interaction may help explain heterogeneity in the gabapentinoid-dementia literature, as prior studies did not stratify by CCB exposure.

The paradoxically weaker interaction in more comorbid patients (CKD ratio, 0.25; stroke ratio, 0.14) provides evidence against confounding by illness severity.[49−52] The observed attenuation may reflect pharmacokinetic changes in multimorbid patients or competing mortality.

Independent replication in the NIH All of Us Research Program substantially strengthens the finding. The convergent evidence across two independent cohorts — with different patient populations, ascertainment mechanisms, and follow-up durations — argues against data-source-specific artifacts.

These findings identify gabapentin-DHP CCB combinations as a target for cognitive safety monitoring. Clinicians should consider baseline cognitive screening before initiating gabapentin in patients taking DHP CCBs, implement enhanced surveillance for cognitive changes, and consider non-DHP antihypertensives for patients at elevated dementia risk.[53−55] If cognitive symptoms develop, medication review should be considered given the potentially reversible nature of drug-induced cognitive impairment.

Strengths This study has several strengths. The active comparator design (pregabalin) eliminates indication bias inherent in comparisons against non-users. The IPTW approach with 18 pre-specified covariates achieved balance on all measured confounders. The multi-layer validation framework—including falsification tests, bootstrap stability, leave-one-site-out replication across 405 facilities, and independent replication in the NIH All of Us Research Program—substantially reduces the probability of a false-positive finding. Dementia subtypes were adjudicated using validated ICD-10 codes, enabling mechanistic inference from the G30/F01 subtype fingerprint.

Limitations

This study has several limitations. First, baseline CCB exposure (any prescription in 180 days) does not confirm concurrent use; days supply data were unavailable. This misclassification would bias toward the null, suggesting estimates may be conservative.[56,57] Second, dementia outcomes relied on ICD-10 codes without clinical validation; while EHR dementia phenotypes have reasonable specificity (0.95),[42–45] misclassification is possible, particularly for drug-induced cognitive impairment. Third, sparse events in non-DHP CCB strata (verapamil n = 348, diltiazem n = 774; combined ~18 events) limit precision of subtype estimates; the non-DHP null finding requires replication in larger samples. Fourth, residual confounding cannot be excluded despite IPTW adjustment; 3 of 7 falsification outcomes showed signals, though the E-value of 3.86 suggests substantial unmeasured confounding would be required. Socioeconomic status and educational attainment are notable unmeasured confounders not captured in the EHR that could contribute to residual confounding.[51,52] Fifth, follow-up was relatively short (median, 1.22 years), therefore the finding may reflect accelerated drug-induced cognitive impairment; the short observed latency (240 days) is consistent with this interpretation. Sixth, these data derive from a single health system in northern New Jersey; however, stability was confirmed across 405 facilities in intrasample replication analyses (detailed in Results), and external replication in the NIH All of Us Research Program supports generalizability. Seventh, ICD-10 coding conventions complicate interpretation of the G30 (Alzheimer disease) signal: clinicians frequently code G30 without the accompanying F00 (dementia due to Alzheimer's disease), and G30 may be assigned at initial diagnostic workup before dementia is clinically established. Some G30-coded patients may represent preclinical Alzheimer pathology rather than drug-induced cognitive impairment, which would complicate the reversibility interpretation. Eighth, hypothyroidism—a common and

treatable cause of reversible cognitive impairment—was not included as a covariate in the current analysis; a sensitivity analysis adding hypothyroidism (ICD-10 E03.x) as a covariate is planned for the revision stage pending extraction from the source EHR. The active comparator design should minimize differential distribution between gabapentin and pregabalin users in the interim. Finally, these findings are hypothesis-generating and require confirmation with validated concurrent exposure measurement, longer follow-up, and clinical cognitive assessments.

Conclusions

We identified a novel drug-drug interaction: DHP CCB co-medication amplifies gabapentin-associated dementia risk. The interaction was particularly strong for DHP CCBs and was confirmed by time-varying analysis and independently replicated in the NIH All of Us Research Program. The selective involvement of neurodegenerative but not vascular dementia subtypes, combined with short latency, suggests potentially reversible drug-induced cognitive impairment mediated by neuronal calcium signaling disruption. Comprehensive validation — including pre-index symptom balance, paradoxically weaker effects in more comorbid patients, strengthening lag analyses, largely null falsification outcomes, null duloxetine comparator, and specificity to $\alpha_2\delta$-binding drugs — is consistent with a true pharmacodynamic interaction. These hypothesis-generating findings identify gabapentin–DHP CCB combinations as a target for cognitive safety monitoring and warrant confirmation in studies with concurrent exposure measurement and clinical cognitive outcomes.

Article Information

Author Contributions: Conceptualization: Green, Tafuto, Gohel. Methodology: Green, Parrott, Gohel. Formal analysis: Green. Data curation: Green, Ljubic, Schulewski. Writing—original draft: Green. Writing—review and editing: Green, Fonseca, Beeri, Sanz Simon, Parrott, Ljubic, Schulewski, Tafuto, Gohel. Supervision: Tafuto, Gohel. All authors had access to the data, contributed to manuscript revisions, and approved the final version.

Conflict of Interest Disclosures: None reported.

Funding/Support: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Computing resources were provided by the Rutgers Office of Advanced Research Computing (Amarel high-performance computing cluster). Access to the NIH All of Us Research Program Controlled Tier was provided through the Researcher Workbench.

Role of the Funder/Sponsor: Not applicable.

Data Sharing Statement: The CRDW dataset used in this study contains de-identified protected health information and is available through the Rutgers Clinical Research Data Warehouse subject to institutional data access agreements and Non-Human Research certification. The NIH All of Us Research Program data are available through the Researcher Workbench (Controlled Tier dataset version C2024Q3R8) to registered researchers who complete the required training and data use agreements (https://www.researchallofus.org). Statistical code is available from the corresponding author upon reasonable request.

Ethics Statement: This study used completely de-identified data and was determined to be Non-Human Subject Research by the Rutgers University Institutional Review Board (Non-Human

Research Self-Certification; PI: Branimir Ljubic; Project: Hypertension — Data Analytics and Computer Science Modeling; certified August 15, 2024, per 45 CFR 46.102(d)). Informed consent was not required. The NIH All of Us Research Program data were accessed under a separate institutional data use agreement.

Additional Information: The STROBE checklist for this study is provided as a supplemental document.

Figure Legends

Figure 1. Study Design and Cohort Composition. Integrated study design panel combining CONSORT-style flow diagram (left) with cohort composition summary (right). Source population: adults aged 40 or older with hypertension and gabapentinoid prescription, Rutgers CRDW, 2018–2024. Final analytic cohort: N = 33,791 (502 dementia events). Gabapentin initiators n = 28,058 (83.0%); pregabalin initiators n = 5,733 (17.0%). CCB exposure at baseline: 18.2% (n = 6,146), predominantly DHP (84.6%). Primary outcome: CCB users HR = 2.22 (P = .0005; interaction P = .004); non-CCB users HR = 1.15 (P = .072).



Figure 2. Drug-Drug Interaction and Validation Analyses. Grouped forest plot displaying hazard ratios (95% CI) on a log scale for gabapentin versus pregabalin among hypertension patients with and without CCB co-medication (N = 33,791). Organized across five conceptual sections: primary interaction, CCB subtype specificity, dementia subtypes (CCB users), sensitivity and replication, and falsification. Significant results shown as colored diamonds; non-significant results as grey circles. Vertical reference line at HR = 1.0.

Figure 2. Drug–Drug Interaction and Validation Analyses

Gabapentin vs pregabalin among hypertension patients with and without CCB co-medication (N = 33,791)



References

1. Strahan AE, Rikard SM, Schmit K, et al. Trends in dispensed gabapentin prescriptions in the United States, 2010 to 2024. Ann Intern Med. 2025. PMID: 41021923

2. Pauly NJ, Delcher C, Slavova S, et al. Trends in gabapentin prescribing in a commercially insured US adult population, 2009-2016. J Manag Care Spec Pharm. 2020;26(3):246-252.

3. Goodman CW, Brett AS. Gabapentin and pregabalin for pain—is increased prescribing a cause for concern? N Engl J Med. 2017;377(5):411-414.

4. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD007938.

5. Eghrari NB, Yazji IH, Yavari B, et al. Risk of dementia following gabapentin prescription in chronic low back pain patients. Reg Anesth Pain Med. 2025. PMID: 40639955

6. Oh GY, Moga DC, Fardo DW, et al. The association of gabapentin initiation with cognitive and behavioral changes in older adults with cognitive impairment. Drugs Aging. 2024;41(7):623-632.

7. Salas M, Hofman A, Bresser J. Confounding by indication. Am J Epidemiol. 1999;149(11):981-983.

8. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the $\alpha_2\delta$ subunit of a calcium channel. J Biol Chem. 1996;271(10):5768-5776.

9. Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42(2):229-236.

10. Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29(3):233-249.

11. Dolphin AC. Calcium channel auxiliary $\alpha_2\delta$ and β subunits: trafficking and one step beyond. Nat Rev Neurosci. 2012;13(8):542-555.

12. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel $\alpha_2\delta$ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28(2):75-82.

13. Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661-669.

14. Shao IY, Brenowitz WL, Yaffe K, et al. Diuretics, renin-angiotensin-aldosterone system agents, and calcium channel blockers and the risk of dementia among people with hypertension. JAMA Neurol. 2025;82(3):280-289.

15. Popović N, Morales-Delgado N, Vidal Mena D, et al. Verapamil and Alzheimer's disease: past, present, and future. Front Pharmacol. 2020;11:562.

16. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341(19):1447-1457.

17. Moosmang S, Haider N, Klugbauer N, et al. Role of hippocampal Cav1.2 Ca2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J Neurosci. 2005;25(43):9883-9892.

18. Bauer EP, Schafe GE, LeDoux JE. NMDA receptors and L-type voltage-gated calcium channels contribute to long-term potentiation. J Neurosci. 2002;22(12):5239-5249.

19. Striessnig J, Koschak A, Sinnegger-Brauns MJ, et al. Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochem Soc Trans. 2006;34(Pt 5):903-909.

20. Thibault O, Landfield PW. Increase in single L-type calcium channels in hippocampal neurons during aging. Science. 1996;272(5264):1017-1020.

21. Mason RP, Leeds PR, Jacob RF, et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem. 1999;72(4):1448-1456.

22. Triggle DJ. Calcium channel antagonists: clinical uses—past, present and future. Biochem Pharmacol. 2007;74(1):1-9.

23. Thibault O, Porter NM, Chen KC, et al. Calcium dysregulation in neuronal aging and Alzheimer's disease: history and new directions. Cell Calcium. 1998;24(5-6):417-433.

24. Sá KN, Moreira L, Baptista AF, et al. Prevalence of chronic pain in developing countries: systematic review and meta-analysis. Pain Rep. 2019;4(6):e779.

25. Berridge MJ. Calcium signalling and Alzheimer's disease. Neurochem Res. 2011;36(7):1149-1156.

26. Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology. Curr Epidemiol Rep. 2015;2(4):221-228.

27. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.

28. Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11(7):437-441.

29. Schneeweiss S, Rassen JA, Brown JS, et al. Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med. 2019;170(6):398-406.

30. Austin PC. An introduction to propensity score methods for reducing the effects of confounding. Multivariate Behav Res. 2011;46(3):399-424.

31. Austin PC, Stuart EA. Moving towards best practice when using IPTW. Stat Med. 2015;34(28):3661-3679.

32. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.

33. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656-664.

34. Crump RK, Hotz VJ, Imbens GW, Mitnik OA. Dealing with limited overlap in estimation of average treatment effects. Biometrika. 2009;96(1):187-199.

35. Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758-764.

36. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268-274.

37. Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias. Epidemiology. 2010;21(3):383-388.

38. Prasad V, Jena AB. Prespecified falsification end points: can they validate true observational associations? JAMA. 2013;309(3):241-242.

39. Arnold BF, Ercumen A. Negative control outcomes: a tool to detect bias in randomized trials. JAMA. 2016;316(24):2597-2598.

40. Tamim H, Monfared AA, LeLorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf. 2007;16(3):250-258.

41. Horwitz RI, Feinstein AR. The problem of “protopathic bias” in case-control studies. Am J Med. 1980;68(2):255-258.

42. Taylor DH Jr, Fillenbaum GG, Ezell ME. The accuracy of Medicare claims data in identifying Alzheimer's disease. J Clin Epidemiol. 2002;55(9):929-937.

43. Jaakkimainen RL, Bronskill SE, Tierney MC, et al. Identification of physician-diagnosed Alzheimer's disease and related dementias in population-based administrative data. J Alzheimers Dis. 2016;54(1):337-349.

44. Wilkinson T, Schnier C, Bush K, et al. Identifying dementia outcomes in UK Biobank: a validation study. Eur J Epidemiol. 2019;34(6):557-565.

45. St Germaine-Smith C, Metcalfe A, Pringsheim T, et al. Recommendations for optimal ICD codes to study neurologic conditions. Neurology. 2012;79(10):1049-1055.

46. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15-28.

47. Larson EB, Kukull WA, Buchner D, Reifler BV. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987;107(2):169-173.

48. Alagiakrishnan K, Wiens CA. An approach to drug induced delirium in the elderly. Postgrad Med J. 2004;80(945):388-393.

49. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303.

50. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149-1156.

51. Haneuse S, VanderWeele TJ, Arterburn D. Using the E-value to assess the potential effect of unmeasured confounding. JAMA. 2019;321(6):602-603.

52. Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Website and R package for computing E-values. Epidemiology. 2018;29(5):e45-e47.

53. Pottegård A, Christensen R, Houji A, et al. Primary non-adherence in general practice. Eur J Clin Pharmacol. 2014;70(6):757-763.

54. Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of "deprescribing." Br J Clin Pharmacol. 2015;80(6):1254-1268.

55. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827-834.

56. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-337.

57. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492-499.

58. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Lancet. 2007;370(9596):1453-1457.

59. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84(408):1074-1078.

60. McDaid J, Mustaly-Kalimi S, Stutzmann GE. Ca2+ Dyshomeostasis Disrupts Neuronal and Synaptic Function in Alzheimer's Disease. Cells. 2020;9(12):2655. doi:10.3390/cells9122655

61. Wang M, Zhang H, Liang J, Huang J, Wu T, Chen N. Calcium signaling hypothesis: A non-negligible pathogenesis in Alzheimer's disease. J Adv Res. 2025;77:513-534. doi:10.1016/j.jare.2025.01.007